GUBBIOTTI, MARILENA
 Distribuzione geografica
Continente #
NA - Nord America 689
EU - Europa 493
AS - Asia 166
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.353
Nazione #
US - Stati Uniti d'America 685
IE - Irlanda 131
IT - Italia 123
SE - Svezia 71
HK - Hong Kong 60
SG - Singapore 39
CN - Cina 32
UA - Ucraina 32
FI - Finlandia 25
GB - Regno Unito 22
KR - Corea 20
NL - Olanda 20
RU - Federazione Russa 18
DE - Germania 15
BE - Belgio 14
FR - Francia 6
VN - Vietnam 5
CA - Canada 4
IN - India 4
SK - Slovacchia (Repubblica Slovacca) 4
AU - Australia 3
PH - Filippine 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
GR - Grecia 2
IR - Iran 2
MK - Macedonia 2
RO - Romania 2
AT - Austria 1
BG - Bulgaria 1
BR - Brasile 1
EU - Europa 1
JP - Giappone 1
Totale 1.353
Città #
Chandler 197
Dublin 131
San Mateo 87
Hong Kong 60
Ann Arbor 46
Altamura 29
Medford 28
Princeton 28
Singapore 27
Andover 24
Lawrence 24
Perugia 22
Wilmington 18
Mondolfo 16
Seoul 15
Brussels 14
Ashburn 13
Beijing 12
Redwood City 10
Des Moines 9
Saint Petersburg 9
Boardman 8
Helsinki 6
Norwalk 6
Dong Ket 5
Los Angeles 5
Bratislava 4
Jacksonville 4
Dasmarinas 3
Florence 3
Moscow 3
Rome 3
San Paolo di Civitate 3
Adelaide 2
Bucharest 2
Castellammare Di Stabia 2
Hefei 2
Houston 2
Lonigo 2
Marino 2
New York 2
Ottawa 2
Ponte 2
Reggio Calabria 2
Vancouver 2
Woodbridge 2
Bari 1
Brescia 1
Brno 1
Buffalo 1
Böblingen 1
Cambridge 1
Chicago 1
Crespino 1
Ergolding 1
Fairport 1
Grugliasco 1
Hangzhou 1
Jinan 1
Kiev 1
Krasnodar 1
Littleport 1
Mainz 1
Milan 1
Monte Urano 1
Nanchang 1
Nanjing 1
Phoenix 1
Praia A Mare 1
Prato 1
Redmond 1
Sydney 1
Tacoma 1
Tappahannock 1
Tokyo 1
Vienna 1
Totale 928
Nome #
The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: a prospective randomized study 97
The efficacy and safety of a multimodal therapy for chronic prostatitis/chronic pelvic pain: a psospective randomized study 85
INFILTRAZIONI INTRADETRUSORIALI DI ONABOTULINUMTOXINA IN PAZIENTI AFFETTI DA SINDROME DELLA VESCICA IPERATTIVA: BEST- PRACTICE MANAGEMENT 82
IncobotulinumtoxinA in the treatment of neurogenic detrusor overactivity. 79
“Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by Multiple Sclerosis: Long term follow up”. 69
Clinical and urodynamic efficacy of Xeomin in the treatment of neurogenic detrusor overactivity: preliminary results. 67
ABDOMINAL VS LAPAROSCOPIC SACROCOLPOPEXY: A RANDOMIZED CONTROLLED TRIAL, FINAL RESULTS 66
OnabotulinumtoxinA intravesical treatment in patients affected by overactive bladder syndrome: best practice in real-life management 64
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 56
Desmopressin in the treatment of nocturia in patients affected by neurogenic bladder 53
ONABOTULINUMTOXIN A INTRADETRUSOR INJECTIONS IN THE TREATMENT OF REFRACTORY DETRUSOR OVERACTIVITY DUE TO PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY 50
BOTULINUM A TOXIN REDUCES THE EXPRESSION OF VANILLOID AND CANNABINOID RECEPTORS IN "IN VITRO" PRIMARY HUMAN SMOOTH MUSCLES CELL CULTURES: PRELIMINARY RESULTS 49
CLINICAL OUTCOMES OF SECOND-LINE TREATMENTS CYCLING IN REFRACTORY WET OVERACTIVE BLADDER PATIENTS BEFORE SWITCHING TO A THIRD-LINE THERAPY: A REAL WORLD OBSERVATIONAL STUDY 49
Intradetrusorial botulinum toxin in patients with multiple sclerosis: A neurophysiological study 45
Bladder and bowel dysfunction, adaptive behaviour and psychiatric profiles in adults affected by autism spectrum disorders 44
OVERACTIVE BLADDER, URINARY INCONTINENCE AND DEPRESSION 44
SEXUAL DYSFUNCTION IN PATIENTS WITH MULTIPLE SCLEROSIS: PREVALENCE AND IMPACT OF SYMPTOMATIC TREATMENTS 43
La disfunzione sessuale nei pazienti con sclerosi multipla: prevalenza e impatto dei trattamenti sintomatici 43
OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results 42
ONABOTULINUM TOXIN A INTRADETRUSORIAL INJECTION MODALITY: SHALL WE TAKE A REST? 41
The Efficacy and Safety of Duloxetine in a Multidrug Regimen for Chronic Prostatitis/Chronic Pelvic Pain Syndrome. 39
EFFECTS OF BOTULINUM TOXIN TYPE A ON THE CELL GROWTH OF NORMAL HUMAN PROSTATE EPITHELIAL CELLS 38
TRATTAMENTO RIPETUTO CON MULTIPLE INFILTRAZIONI INTRADETRUSORIALI DI ONABOTULINUMTOSSINA A IN PAZIENTI AFFETTI DA VESCICA IPERATTIVA REFRATTARIA: RISULTATI A LUNGO TERMINE. 37
Desmopressin in the treatment of nocturia in patients affected by Parkinson's disease 36
Urodynamic findings and functional outcomes after laparoscopic sacrocolpopexy for symptomatic pelvic organ prolapse 32
Urinary symptoms and sexual dysfunction in patients affected by multiple sclerosis 28
Pharmacologic goals in interstitial cystitis/bladder pain syndrome 23
Correlation between high pd-l1 and emt/invasive genes expression and reduced recurrence-free survival in blood-circulating tumor cells from patients with non-muscle-invasive bladder cancer 19
Totale 1.420
Categoria #
all - tutte 5.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.671


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202097 3 11 4 6 4 1 26 7 11 6 8 10
2020/2021155 5 4 7 8 55 17 12 3 17 10 7 10
2021/2022262 8 73 2 18 5 0 7 74 2 9 30 34
2022/2023527 37 98 5 84 31 51 0 19 170 2 20 10
2023/2024185 13 12 13 5 1 1 62 1 2 7 34 34
2024/202515 15 0 0 0 0 0 0 0 0 0 0 0
Totale 1.420